ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q4 2023 Earnings Conference Call July 7, 2023 10:30 AM ET

Company Participants

Jennifer Bath - CEO

Barry Duplantis - VP-Client Relations

Ilse Roodink - Chief Scientific Officer

Brad McConn - CFO

Conference Call Participants

Will McHale - Ingalls & Snyder

Ramakanth Swayampakula - H.C. Wainwright

Michael Freeman - Raymond James

Operator

Good morning, ladies and gentlemen. Thank you for joining us today for IPA's earnings call covering the fourth quarter and full fiscal year of 2023. I am Regina, and I have the privilege of hosting this call.

Before we commence, I would like to draw your attention to the fact that our discussion today may include forward-looking statements. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from what we express or imply. We strongly encourage you to review our filings with the Securities and Exchange Commission for a comprehensive discussion of these risks and uncertainties. IPA remains committed to complying with legal requirements and will update forward-looking statements only as mandated by law.

During today's conference call as well as in the accompanying presentation slides, we will be employing non-GAAP financial measures to assist investors and analysts in comprehending IPA's business performance. Adjusted EBITDA in particular allows for meaningful comparisons and analysis of trends in our business over different periods. For a detailed explanation and reconciliation of these non-GAAP measures to GAAP measures, please refer to the management discussion and analysis section of our filing on EDGAR and SEDAR.

Now without further ado, I would like to pass the floor to IPA's CEO, Dr. Jennifer Bath, who will provide an overview of our quarterly results.

Jennifer Bath

Thank you, Regina.

During today's call, we aim to provide you with a clear and comprehensive understanding of IPA, our company. And how we are strategically positioning ourselves as leaders in the field of AI and antibody therapeutics.

At ImmunoPrecise Antibodies we are consistently paving the way as pioneers in technology, positioning our company as a front runner in innovation. Our mission is to harness the potential of data driven AI and cutting-edge laboratory technologies to deliver groundbreaking solutions. We set ourselves apart by employing patented technologies and trade secrets that provide unparalleled insights into the realm of biological data.

Let's begin today's call by highlighting the significant achievements and developments of the past fiscal year. These key milestones not only showcase our unique position in the market but also reflect the progress we have made over the last 12 months.